JP6976579B2 - 新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用 - Google Patents

新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用 Download PDF

Info

Publication number
JP6976579B2
JP6976579B2 JP2018548761A JP2018548761A JP6976579B2 JP 6976579 B2 JP6976579 B2 JP 6976579B2 JP 2018548761 A JP2018548761 A JP 2018548761A JP 2018548761 A JP2018548761 A JP 2018548761A JP 6976579 B2 JP6976579 B2 JP 6976579B2
Authority
JP
Japan
Prior art keywords
seq
human
met
microglobulin
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018548761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519466A5 (enExample
JP2019519466A (ja
Inventor
ヴェステル ローゼンロフ，レナ
エドストレーム ヘーゲルヴァール，アンネリ
アケルストロム，ボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guard Therapeutics International AB
Original Assignee
Guard Therapeutics International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guard Therapeutics International AB filed Critical Guard Therapeutics International AB
Publication of JP2019519466A publication Critical patent/JP2019519466A/ja
Publication of JP2019519466A5 publication Critical patent/JP2019519466A5/ja
Application granted granted Critical
Publication of JP6976579B2 publication Critical patent/JP6976579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2018548761A 2016-03-18 2017-03-17 新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用 Active JP6976579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670158 2016-03-18
DKPA201670158 2016-03-18
PCT/EP2017/056436 WO2017158181A1 (en) 2016-03-18 2017-03-17 Novel alpha-1-microglobulin derived proteins and their use

Publications (3)

Publication Number Publication Date
JP2019519466A JP2019519466A (ja) 2019-07-11
JP2019519466A5 JP2019519466A5 (enExample) 2020-04-23
JP6976579B2 true JP6976579B2 (ja) 2021-12-08

Family

ID=56080208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548761A Active JP6976579B2 (ja) 2016-03-18 2017-03-17 新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用

Country Status (15)

Country Link
US (1) US10981963B2 (enExample)
EP (1) EP3430032B1 (enExample)
JP (1) JP6976579B2 (enExample)
KR (1) KR102437662B1 (enExample)
CN (1) CN108779157B (enExample)
AU (1) AU2017235608B2 (enExample)
BR (1) BR112018068522A2 (enExample)
CA (1) CA3017836A1 (enExample)
EA (1) EA039776B1 (enExample)
ES (1) ES2896734T3 (enExample)
MX (1) MX2018011193A (enExample)
NZ (1) NZ746677A (enExample)
SG (1) SG11201807352XA (enExample)
WO (1) WO2017158181A1 (enExample)
ZA (1) ZA201805797B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511386A (zh) * 2017-11-03 2020-08-07 卫士医疗国际公司 α-1-微球蛋白用于保护骨髓细胞的用途
WO2024165674A1 (en) 2023-02-08 2024-08-15 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof
US12227343B2 (en) * 2023-03-17 2025-02-18 Blue Buffalo Enterpises, Inc. Retail ready opening feature for e-commerce carton

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2313106B1 (en) * 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2013113851A1 (en) * 2012-01-31 2013-08-08 Technische Universitaet Muenchen Muteins of a1m lipocalin and method of production therefor
ES2599034T3 (es) * 2012-09-05 2017-01-31 A1M Pharma Ab Alfa-1-microglobulina para su uso en el tratamiento de enfermedades relacionadas con mitocondrias
WO2014047490A1 (en) * 2012-09-21 2014-03-27 Beintoo, S.P.A. Interactive experience fully contained within an expandalble embedded unit
US10226570B2 (en) * 2017-03-10 2019-03-12 Seton Healthcare Family Apparatus and method for temporarily securing a movable accessory device relative to a movable patient

Also Published As

Publication number Publication date
SG11201807352XA (en) 2018-09-27
ES2896734T3 (es) 2022-02-25
WO2017158181A1 (en) 2017-09-21
JP2019519466A (ja) 2019-07-11
NZ746677A (en) 2023-02-24
EP3430032A1 (en) 2019-01-23
CN108779157B (zh) 2022-12-30
US10981963B2 (en) 2021-04-20
BR112018068522A2 (pt) 2019-01-22
US20190161524A1 (en) 2019-05-30
EA201892085A1 (ru) 2019-02-28
KR102437662B1 (ko) 2022-08-29
EP3430032B1 (en) 2021-09-01
EA039776B1 (ru) 2022-03-11
CN108779157A (zh) 2018-11-09
ZA201805797B (en) 2022-03-30
CA3017836A1 (en) 2017-09-21
AU2017235608A1 (en) 2018-10-18
MX2018011193A (es) 2019-03-28
KR20180127411A (ko) 2018-11-28
AU2017235608B2 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US20220370560A1 (en) Ptd-smad7 therapeutics
JP6976579B2 (ja) 新規アルファ−１−マイクログロブリン由来タンパク質ならびにそれらの使用
DK2900254T3 (en) ALFA-1 MICROGLOBULIN TO USE IN THE TREATMENT OF MITOCONDRY-RELATED DISEASES
Åkerström et al. rA1M-035, a Physicochemically improved human recombinant α1-microglobulin, has therapeutic effects in rhabdomyolysis-induced acute kidney injury
US7863017B2 (en) TAT-utrophin as a protein therapy for dystrophinopathies
Yang et al. Decorin is a Zn2+ metalloprotein
Fritzinger et al. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion
TW201643199A (zh) 用於放射性核種治療中保護腎臟之α－１－微球蛋白
KR101131512B1 (ko) 퇴행성신경질환 예방 또는 치료용 약제학적 조성물
CA2247998C (en) Fragments of cr1 and their use
CN1944460B (zh) Alr多肽及其应用
JP2005168329A (ja) Ｎａｄｐｈオキシダーゼ活性を阻害するポリペプチド
AU2024219294A1 (en) Alpha-1-microglobulin derived peptide fragments and uses thereof
WO2010077260A1 (en) Pegylated hemoglobins stabilized at valine-1(alpha), methods of preparation and uses thereof
EP2404613B1 (en) Novel uses of fibrinogen-420 and active domain thereof

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6976579

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250